Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

(2015) Libo Zhang et al.   NEOPLASIA

Low-Dose Cyclophosphamide Selectively Decreases Regulatory T Cells and Inhibits Angiogenesis in Dogs with Soft Tissue Sarcoma

(2011) J.H. Burton et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11

(2010) Emmalena Gregory-Bryson et al.   BMC CANCER

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Phenotypic and functional characterization of a CD4+ CD25high FOXP3high regulatory T-cell population in the dog

(2010) Dammy Pinheiro et al.   IMMUNOLOGY

A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model

(2010) Ladan Langroudi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma

(2010) B.J. Biller et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs

(2010) M. F. YANCEY et al.   JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma Model

(2010) Zhuoshun Yang et al.   PLoS One

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision

(2009) C. A. London et al.   CLINICAL CANCER RESEARCH

Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas

(2009) R.E. Elmslie et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Relationship between regulatory and type 1 T cells in dogs with oral malignant melanoma

(2009) Yutaka Horiuchi et al.   MICROBIOLOGY AND IMMUNOLOGY

Tyrosine Kinase Inhibitors in Veterinary Medicine

(2009) Cheryl A. London   Topics in Companion Animal Medicine

A novel monoclonal antibody specific for canine CD25 (P4A10): Selection and evaluation of canine Tregs

(2009) V. Kraig Abrams et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy

(2008) J. A. Blansfield et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias

(2008) Suzanne G. Usher et al.   EXPERIMENTAL HEMATOLOGY

Comparative methodologies of regulatory T cell depletion in a murine melanoma model

(2008) Norimasa Matsushita et al.   JOURNAL OF IMMUNOLOGICAL METHODS